Detecting HLA loss of heterozygosity within a standard diagnostic sequencing workflow for prognostic and therapeutic opportunities

Abstract To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved clinical diagnostic test, Tempus xT CDx. Validation was conducted via: (1) analytical evaluation of 17 arc...

Descrición completa

Detalles Bibliográficos

Principais autores:	Ariane Lozac’hmeur, Tyler Danek, Qidi Yang, Mario G. Rosasco, John S. Welch, William Y. Go, Eric W. Ng, Armen Mardiros, David G. Maloney, Edward B. Garon, Kedar Kirtane, Diane M. Simeone, Julian R. Molina, Ameen A. Salahudeen, Michelle M. Stein, J. Randolph Hecht
Formato:	Artigo
Idioma:	Inglês
Publicado:	Nature Portfolio 2024-08-01
Series:	npj Precision Oncology
Acceso en liña:	https://doi.org/10.1038/s41698-024-00665-z
Tags:	Engadir etiqueta Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!